As more Asia biotechs turn to regenerative medicine to address disorders without a cure, Medipost Inc. is continuing global ...

Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition following SARS-CoV-2 infection ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

Owlstone Medical Ltd. recently secured $27 million in the first close of its series E financing round for clinical trials and product commercialization based on its Breath Biopsy platform technology.

The European Union has implemented legislation governing artificial intelligence (AI) with more on tap, but the U.S. has to date lagged in that area. However, the House of Representatives has ...

Biopharma companies secured $102.15 billion in funding in 2024, a 44% increase from $70.97 billion in the full-year 2023 and significantly higher than the $60.81 billion raised in 2022. December ...

A 6.5-month-old boy with the rare inherited urea cycle disorder ornithine transcarbamylase (OTC) deficiency has responded positively in a targeted in vivo gene editing trial, in which a correct copy ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with projections pointing to antimicrobial ...

Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA therapeutic targeting cannabinoid CB1 receptor (CB1R) and zinc finger protein ...

In BioWorld ’s new report, Healing the health divide, we’ve highlighted the disparities.

TC Biopharm (Holdings) plc intends to begin proof-of-concept preclinical studies for its lead therapeutic TCB-008, to treat H5N1, or bird flu. TCB-008 is an allogeneic, unmodified cell therapy ...